Radium 223 (Xofigo(R))

Xofigo is a drug known as a radiopharmaceutical that is engineered to fight metastatic prostate cancer. The drug consists of two parts: (1.) a localizing element that helps find and target prostate cancer that is involving the bone and (2.) a short-range radioactive particle that is designed to fight these prostate cancer cells. Xofigo is highly targette in that the prostate cancer sees a relatively high-dose of radiation while the rest of normal, healthy tissues are generally spared — clinical trials have shown efficacy with relatively few side-effects.

Xofigo is an important option for men with advanced prostate cancer.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean in efficitur sapien, quis rutrum turpis. Maecenas lectus ipsum, lobortis ac aliquam eu, faucibus quis libero. Nam sed leo a justo facilisis congue. Proin et venenatis diam. Fusce nec ante id purus condimentum sagittis. Sed semper porta maximus. Duis eu lacinia neque. Maecenas ut euismod augue.

-Oliver Sartor

Request an Appointment